Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.135, Iss.2, 2012-09, pp. : 505-517

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cross-platform meta-analysis of multiple gene expression profiles identifies novel expression signatures in acquired anthracycline-resistant breast cancer

Oncology Reports, Vol. 33, Iss. 4, 2015-01 ,pp. : 1985-1993

Spandidos Publications

Access to resources Recommend Favorite

JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib

Oncology Letters, Vol. 9, Iss. 2, 2015-01 ,pp. : 757-761

Spandidos Publications

Access to resources Recommend Favorite

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells

By Arun Banu Akar Ugur Gutierrez-Barrera Angelica M. Hortobagyi Gabriel N. Ozpolat Bulent

International Journal of Oncology, Vol. 47, Iss. 1, 2015-07 ,pp. : 262-268

Spandidos Publications

Access to resources Recommend Favorite

A Pathway-Based Approach to Identify Molecular Biomarkers in Cancer

By Stevenson Marvaretta Potti Anil

Annals of Surgical Oncology, Vol. 19, Iss. 3, 2012-07 ,pp. : 620-624

Springer Publishing Company

Access to resources Recommend Favorite

The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition

International Journal of Oncology, Vol. 44, Iss. 3, 2014-01 ,pp. : 735-744

Spandidos Publications

Access to resources Recommend Favorite